Envestnet Asset Management
KYMR icon

Envestnet Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Envestnet Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$985K Buy
8,586
+2,530
+42% +$217K ﹤0.01% 3640
2026
Q1 		$504K Buy
6,056
+943
+18% +$74.7K ﹤0.01% 3932
2025
Q4 		$398K Buy
+5,113
New +$345K ﹤0.01% 3854

Other funds holding KYMR

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Envestnet Asset Management's KYMR Position: Q2 2026 in Review

Envestnet Asset Management increased its Kymera Therapeutics (KYMR) stake by 42% in Q2 2026, buying an estimated $217K and bringing the position to 8,586 shares worth $985K. The position accounts for ﹤0.01% of the portfolio, ranked #3640.

Envestnet Asset Management first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Envestnet Asset Management held 8,586 shares of Kymera Therapeutics worth $985K as of Q2 2026.
  • Envestnet Asset Management bought 2,530 Kymera Therapeutics shares in Q2 2026, an estimated $217K.
  • Kymera Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3640 holding.
  • Envestnet Asset Management first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.